This double-blind, placebo-controlled, full cross-over trial (n=30) will study the effects of psilocybin (10mg/70kg) on brain activity and thought dynamics in healthy volunteers.
Status: Recruiting
Start date: 2022-03-03
Phase I
Blinded
30 participants
Interventional
Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression
This randomised, double-blind, controlled trial (n=60) will examine the rapid antidepressant effects of psilocybin (5mg) compared to ketamine (50mg) in patients with treatment-resistant depression (TRD).
Status: Recruiting
Start date: 2019-03-05
Phase II
Blinded
60 participants
Interventional
This therapeutic exploratory Phase II trial (n=44) aims to assess the effects of low doses of psilocybin (5-10mg) on pain endurance and ratings of painfulness in fibromyalgia patients and healthy volunteers.
Status: Recruiting
Start date: 2021-12-22
Phase II
Blinded
44 participants
Interventional
This randomised placebo-controlled parallel-group multi-centre trial (n=100; withdrawn) aimed to study the efficacy of ketamine infusion (35mg/70kg) in relieving symptoms of depression among patients who did not respond adequately to conventional treatment.
Status: Withdrawn
Start date: 2006-06-09
Not Applicable
Open
100 participants
Interventional
This double-blind, placebo-controlled trial (n=160) aims to evaluate the efficacy and safety of Psilocybin-Assisted Psychotherapy (25mg) in adults with Alcohol Use Disorder (AUD).
Status: Active, not recruiting
Start date: 2022-06-01
Phase II
Blinded
160 participants
Interventional
This double-blind, placebo-controlled trial (n=112) conducted by the University Medical Centre Groningen in the Netherlands aims to explore the efficacy and feasibility of intranasal ketamine (75mg) in addressing acute suicidality (SI).
Status: Active, not recruiting
Start date: 2021-06-08
Phase II
Blinded
112 participants
Interventional
This completed therapeutic exploratory Phase II trial of ketamine for treatment-resistant depression (TRD) and bipolar disorder (BD), was conducted in Belgium by UZ Leuven, a non-commercial sponsor.
Status: Completed
Start date: 2016-07-27
Phase II
Blinded
120 participants
Interventional
This open-label trial (n=10) investigates the feasibility of a future randomized controlled trial (RCT) on the efficacy of oral esketamine in treating depression and demoralization in advanced cancer patients receiving palliative care.
Status: Active, not recruiting
Start date: 2020-09-17
Phase II
Open
10 participants
Interventional
This double-blind, placebo-controlled, Phase II trial (n=60) of ketamine and therapy (CBASP) for chronic depression (MDD) is being conducted in Germany by the University Hospital Tuebingen.
Status: Active, not recruiting
Start date: 2019-07-19
Phase II
Blinded
60 participants
Interventional
This double-blind, randomised, placebo-controlled Phase II trial (n=60) conducted in Germany by Ketabon explores the efficacy, safety, and tolerability of add-on treatment with ketamine prolonged-release tablets (KET01, 120 mg or 240 mg once daily) in outpatients with treatment-resistant depression (TRD).
Status: Completed
Start date: 2022-01-28
Phase II
Blinded
60 participants
Interventional
This randomised, double-blind, placebo-controlled trial (n=100) sponsored by UZ Leuven / KU Leuven in Belgium (S60859) explores the use of ketamine in acute brain injury (TBI) patients to study its effects on Therapy Intensity Level (TIL) and intracranial pressure (ICP).
Status: Active, not recruiting
Start date: 2020-10-30
Phase IV
Blinded
100 participants
Interventional
This double-blind, placebo-controlled trial (n=180) investigated the potential benefits of ketamine augmentation during electroconvulsive treatment (ECT) to improve outcomes in depression (MDD).
Status: Completed
Start date: 2012-01-25
Phase IV
Blinded
180 participants
Interventional
This completed interventional trial (n=20) conducted in Ireland by the Department of Psychiatry aimed to assess the efficacy and safety of intravenous ketamine in patients with Selective Serotonin Reuptake Inhibitor (SSRI)-Resistant Depression (TRD).
Status: Completed
Start date: 2011-08-08
Phase II
Open
20 participants
Interventional
This double-blind, placebo-controlled therapeutic exploratory trial (n=60) conducted by the University of Cyprus, investigates the efficacy of ketamine in preventing relapse in patients with Opioid-Use Disorders (OUD). The trial, named PROUD, is currently ongoing.
Status: Active, not recruiting
Start date: 2022-04-28
Phase II
Blinded
60 participants
Interventional
This Phase I, multi-centre, double-blind, placebo-controlled parallel group study (n=60; terminated) aimed to assess the pharmacoMRI effects of AZD6765 and ketamine in male and female patients with depression (MDD).
Status: Terminated
Start date: 2009-08-17
Phase I
Blinded
60 participants
Interventional
This parallel-group, randomised, controlled trial (n=104) investigates the efficacy of ketamine as an adjunctive therapy for major depression (MDD).
Status: Recruiting
Start date: 2021-09-13
Phase III
Open
104 participants
Interventional
This double-blind, randomised, placebo-controlled Phase II trial (n=88) was conducted in Poland by Celon Pharma SA The study aimed to assess the efficacy, safety, and pharmacokinetics of inhaled Esketamine in subjects aged 18-65 with treatment-resistant bipolar depression.
Status: Completed
Start date: 2018-07-30
Phase II
Blinded
88 participants
Interventional
This randomised controlled cross-over pilot study (n=20) investigates the efficacy of esketamine in treating depressive and negative symptoms in patients (ages 18-64) with schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Status: Active, not recruiting
Start date: 2021-09-07
Phase III
Blinded
20 participants
Interventional
This Phase IV trial (n=72), conducted by the Department of Psychiatry, Helsinki University Central Hospital in Finland, is a placebo-controlled study investigating the effect of intranasal ketamine on suicidality in severely depressed (MDD) and suicidal patients (SI).
Status: Active, not recruiting
Start date: 2015-04-30
Phase IV
Blinded
72 participants
Interventional
This open-label, non-randomised feasibility study (n=32) investigates the use of low-dose individually-tailored subcutaneous ketamine infusion for treating depression in palliative care patients with advanced life-limiting illnesses.
Status: Planned
Start date: 2019-09-16
Phase II
Blinded
10 participants
Interventional
This interventional trial (n=24) investigates the effects of ketamine (26-52mg/70kg) on mood and eating disorder cognitions in enduring anorexia nervosa (AN).
Status: Not yet recruiting
Start date: 2019-09-02
Phase II
Blinded
24 participants
Interventional
This open-label trial (n=24) investigates the efficacy of subcutaneous ketamine (21-42mg/70kg) for treating depression (MDD) in elderly patients.
Status: Recruiting
Start date: 2018-09-24
Phase II
Open
24 participants
Interventional
This phase IIa multi-center, randomized, subject, and investigator-blinded, placebo-controlled, active comparator, parallel-group proof-of-concept study (n=66) investigates the efficacy, safety, tolerability, and pharmacokinetics of MIJ821 in patients (aged 18-65) with treatment-resistant depression (TRD).
Status: Completed
Start date: 2019-04-12
Phase II
Blinded
66 participants
Interventional
This randomised, double-blind, placebo-controlled, parallel-group trial (n=55) sponsored by Novartis Farmacéutica, S.A., in collaboration with Novartis Pharma AG, aims to evaluate the efficacy, safety, tolerability, and pharmacokinetics of a single subcutaneous injection of MIJ821 (NMDA receptor activity like ketamine) in addition to standard care for participants with treatment-resistant depression (TRD).
Status: Planned
Start date: 2022-08-29
Phase II
Blinded
55 participants
Interventional
This randomised, double-blind, placebo-controlled trial (n=24) investigates the role of CYP2D6 in the pharmacokinetics of ibogaine (20mg) in healthy volunteers.
Status: Completed
Start date: 2013-07-01
Phase I
Blinded
21 participants
Interventional
This randomised controlled trial (n=50) investigates the effects of low-dose intramuscular ketamine on depression ratings in individuals with major depressive disorder (MDD) and cancer in palliative care.
Status: Recruiting
Start date: 2011-03-23
Phase II
Blinded
50 participants
Interventional
This randomised controlled trial (n=24) investigates the rapid alleviation of depression in individuals with coexisting alcohol dependence (AUD), utilising ketamine at sub-anaesthetic doses (7-140mg/70kg intramuscular).
Status: Not yet recruiting
Start date: 2010-09-01
Phase II
Blinded
24 participants
Interventional
This double-blind, placebo-controlled crossover trial (n=21) investigated whether memantine can mitigate memory impairment induced by MDMA in humans.
Status: Completed
Start date: 2011-05-01
Not Applicable
Blinded
21 participants
Interventional
This interventional trial (n=18; status unknown) aims to explore the impact of oxytocin and the 5-HT1A receptor on MDMA-induced prosocial behaviour.
Status: Unknown status
Start date: 2011-02-01
Blinded
18 participants
Interventional
This randomised, double-blinded, 4 arm parallel adaptive trial (n=140) aims to explore the therapeutic benefits, tolerability, and acceptability of psychedelic therapy using psilocybin for treatment-resistant depression (TRD).
Status: Not yet recruiting
Start date: 2024-02-05
Phase II
Blinded
140 participants
Interventional
Find Psychedelic Trials
Browse through all psychedelic trials that have been done or are ongoing. These trials, usually double-blind, placebo-controlled studies, are the core of psychedelic research. The outcome of these trials will determine the future of psychedelics as medicine.
The trials included in our database come from ClinicalTrials.Gov and from the various companies pursuing psychedelics as medicine. Most of the trials have been funded by universities, though companies and governments are currently starting to ramp up their involvement.
?>